The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
 
Maciej Jerzy Krzakowski
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Janssen; Roche
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; Menarini; Pfizer; PrIME Oncology; Roche; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca; BMS; Hansoh; Hengrui Therapeutics; Hutchison MediPharma; Roche
 
Sophie Cousin
No Relationships to Disclose
 
Egbert F. Smit
Honoraria - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Merck KGaA; Merck KGaA
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Christoph Springfeld
Consulting or Advisory Role - Bayer; Eisai; MSD; Roche; SERVIER
Travel, Accommodations, Expenses - Servier
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Lilly Japan; Merck; Novartis; Ono Pharmaceutical; Otsuka; Takeda
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace; Takeda
Research Funding - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Turning Point Therapeutics
 
Pilar Garrido
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim (I); Bristol-Myers Squibb; Gebro Pharma (I); GlaxoSmithKline; Janssen Biotech (I); Janssen Oncology; Lilly; MSD Oncology; Nordic Group (I); Novartis/Pfizer; Pfizer; Roche Pharma AG; Takeda
Speakers' Bureau - AstraZeneca; BMS; Boehringer Ingelheim; Boehringer Ingelheim (I); Janssen (I); Janssen Oncology; Medscape; MSD Oncology; Nordic Group (I); Novartis; Pfizer; Roche Pharma AG; Takeda; touchIME
Other Relationship - IO Biotech; Janssen Oncology; Novartis
 
Christine H. Chung
Consulting or Advisory Role - Exelixis; Merck; Sanofi/Regeneron
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Brooklyn ImmunoTherapeutics (Inst); Ignyta (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst)
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Victoria J. Bray
No Relationships to Disclose
 
Bethany Pitcher
Employment - Roche
 
Harald Zeuner
Employment - Roche
 
Siddhartha Patel
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Walter Bordogna
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Hans Gelderblom
Research Funding - Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)